A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

NCT00874887 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Anti-biotic Resistance

Interventions

DRUG: moxifloxacin 0.5% HCI ophthalmic solution
DRUG: gatifloxacin ophthalmic solution 0.3%

Sponsor

Allergan